Pierre P.
- Country
- France
- Department
- Hématologie Clinique
Research Overview
- Efficacy of Venetoclax Plus Cytarabine Versus Idarubicin Plus Cytarabine in Post-Remission Therapy for Elderly Patients with Acute Myeloid Leukemia
- Evaluation of CC-95251 Monotherapy and in Combination with Antineoplastic Agents in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Phase 1 Multicenter Dose-Escalation Study of Daratumumab with Idarubicin and Cytarabine or CPX-351 in Patients Aged 60+ with Adverse Risk Acute Myeloblastic Leukemia
Data & Insights
Has run more than one trial at 125 of 305 partner sites.
Specializations
Acute Myeloid Leukemia Focus
The investigator specializes in treating acute myeloid leukemia (AML), with particular emphasis on both newly diagnosed and relapsed/refractory cases. Their expertise extends to managing FLT3-mutated AML and NPM1-mutated AML.
- Refractory AML Treatment
- Novel Therapeutic Combinations
- Targeted Molecular Therapies
Their work includes specialized approaches for elderly patients and those with adverse risk factors.
Hematologic Malignancies
The investigator's expertise encompasses various blood disorders including myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). They focus on developing innovative treatment strategies for these conditions.
- Higher-Risk MDS Management
- Combined Therapy Approaches
- Treatment-Naïve Patient Care
Their research extends to immunotherapy applications in hematologic conditions.
Treatment Innovation
The investigator explores novel therapeutic agents including venetoclax combinations, menin-MLL inhibitors, and FLT3 inhibitors. Their work involves evaluating new treatment platforms and vaccination strategies for leukemia patients.
- Drug Combination Studies
- Immunotherapy Integration
- Treatment De-escalation Strategies
They focus on developing personalized treatment approaches based on molecular markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.